Navigation Links
AXIS II PR Post Refractive

ProductsAXIS II PR Post Refractive
Company Quantel Medical, Inc.
Item AXIS II PR Post Refractive
Features 
  • Precision A-Scan - Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media1
  • Scleral spike discrimination software eliminates optic nerve scans
  • Addresses the biometry challenge of "K correction in post-refractive eyes with 6 post-refractive formulas
  • 6 Formulas for Normal eyes
  • .25 and .50 increment IOL Powers
Description The number of patients requiring cataract surgery following refractive surgery grows larger each year. This has created a challenge for surgeons, as calculating IOL power for a modified cornea is difficult. True corneal power following RK, ALK, PRK and LASIK is difficult to accurately measure by keratometry or topography. For example, keratometry and simulated keratometry by topography will typically overestimate central corneal power in patients who have undergone keratorefractive surgery. With these concerns in mind, Quantel Medical has developed the new Axis II PR (post refractive) biometer. Based upon the patients historical data, doctors can choose from six post-refractive formulas. Additionally six standard IOL formulas are available. The six post-refractive formulas are: Double K/SRK-T, History Derived, Refraction Derived, Shammas, Rosa, and Contact Lens Method. The other six standard formulas are: SRK T, Holladay, Hoffer Q, Haigis, SRK II and Binkhorst II. IOL calculations can be displayed in .25D or .50D increments. With established clinical efficacy equivalent to the laser interferometer, the Axis II PR is intuitive and easy to use. A discrimination feature automatically eliminates optic nerve scans. An onsite inservice and a Prager Immersion Shell are always included.
Info Quantel Medical, Inc.
Customer Service: (888) 660-6726
Web site: http://www.quantelmedical.com

Related medicine products :

1. Slade Refractive Spatula
2. Slade Refractive Speculum
3. OPD-Scan Refractive Power / Corneal Analyzer
4. OPD-Scan II Refractive Power / Corneal Analyzer
5. NaturaLens™ Series Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal)
6. NaturaLens™ Series Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal)
7. Single Piece PMMA Lens (Refractive and Bifocal)
8. ReZoom Refractive Multifocal IOL
Breaking Medicine News(10 mins):Health News:Wisconsin Department of Transportation Chooses EF Johnson Technologies, Inc. for Statewide First Responder Communications System in $13.2 Million Contract 2Health News:Wisconsin Department of Transportation Chooses EF Johnson Technologies, Inc. for Statewide First Responder Communications System in $13.2 Million Contract 3Health News:The Institute of Women's Health of North America to Offer Free Chlamydia Testing at All Affiliated Campuses – Dr. Abdul Rao 2Health News:The Institute of Women's Health of North America to Offer Free Chlamydia Testing at All Affiliated Campuses – Dr. Abdul Rao 3Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2Health News:Study highlights lack of patient knowledge regarding hospital medications 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 3
Breaking Medicine Technology:SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 2SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 3NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Living in U S May Raise Hispanics Cancer Risk 53835 1Living in U S May Raise Hispanics Cancer Risk 53835 2Living in U S May Raise Hispanics Cancer Risk 53835 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 1Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 2Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 3Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 4Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 5Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 6Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 7Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 8Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 9Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 10Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 11Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 12Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 13Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 14Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 15Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 16Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 17Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 18Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 19Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 20Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 21Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 22Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 23Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 24Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 25Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 26Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 27Angiotech Pharmaceuticals Inc announces financial results for the second quarter ended June 30 2009 13411 28Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference 53829 1